{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:38:16Z","timestamp":1793029096959,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Seedling Engineering project of Sichuan Science and Technology Department","award":["2022JDRC0145"],"award-info":[{"award-number":["2022JDRC0145"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-64223-0","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T08:02:27Z","timestamp":1724140947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Physiologically-based pharmacokinetic\/pharmacodynamic modeling of meropenem in critically ill patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Yujie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lvye","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"10","key":"64223_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1164\/rccm.201911-2226LE","volume":"201","author":"B Huttner","year":"2020","unstructured":"Huttner, B. et al. 2019 community-acquired pneumonia treatment guidelines: There is a need for a change toward more parsimonious antibiotic use. Am. J. Respir. Crit. Care Med. 201(10), 1315\u20131316 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"64223_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink, R. G. et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): A randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 21(2), 213\u2013225 (2021).","journal-title":"Lancet Infect. Dis."},{"issue":"6","key":"64223_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts, J. A. et al. Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions. Lancet Infect. Dis. 14(6), 498\u2013509 (2014).","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"64223_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/microorganisms9071505","volume":"9","author":"CB Roger","year":"2021","unstructured":"Roger, C. B. Louart, beta-lactams toxicity in the intensive care unit: An underestimated collateral damage?. Microorganisms 9(7), 1505 (2021).","journal-title":"Microorganisms"},{"issue":"1","key":"64223_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"M Grimstein","year":"2019","unstructured":"Grimstein, M. et al. Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and drug administration\u2019s office of clinical pharmacology. J. Pharm. Sci. 108(1), 21\u201325 (2019).","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"64223_CR6","first-page":"16","volume":"49","author":"YW Jin","year":"2014","unstructured":"Jin, Y. W. & Ma, Y. M. Progress in methodology of establishing physiologically based pharmacokinetic models. Yao Xue Xue Bao 49(1), 16\u201322 (2014).","journal-title":"Yao Xue Xue Bao"},{"issue":"4","key":"64223_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s10156-003-0279-X","volume":"9","author":"DP Nicolau","year":"2003","unstructured":"Nicolau, D. P. Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. J. Infect. Chemother. 9(4), 292\u2013296 (2003).","journal-title":"J. Infect. Chemother."},{"issue":"8","key":"64223_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/10408440802194931","volume":"38","author":"O Pelkonen","year":"2008","unstructured":"Pelkonen, O. et al. Local kinetics and dynamics of xenobiotics. Crit. Rev. Toxicol. 38(8), 697\u2013720 (2008).","journal-title":"Crit. Rev. Toxicol."},{"issue":"3","key":"64223_CR9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/bcp.14456","volume":"87","author":"FS Martins","year":"2021","unstructured":"Martins, F. S. et al. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. Br. J. Clin. Pharmacol. 87(3), 1012\u20131023 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"64223_CR10","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1378\/chest.127.5.1752","volume":"127","author":"J Ramsdell","year":"2005","unstructured":"Ramsdell, J., Narsavage, G. L. & Fink, J. B. Management of community-acquired pneumonia in the home: An American college of chest physicians clinical position statement. Chest 127(5), 1752\u20131763 (2005).","journal-title":"Chest"},{"issue":"5","key":"64223_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ijantimicag.2017.01.009","volume":"49","author":"C Economou","year":"2017","unstructured":"Economou, C. et al. Impact of beta-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int. J. Antimicrob. Agents 49(5), 589\u2013594 (2017).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"64223_CR12","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/cc10441","volume":"15","author":"J Goncalves-Pereira","year":"2011","unstructured":"Goncalves-Pereira, J. & Povoa, P. Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of beta-lactams. Crit. Care 15(5), R206 (2011).","journal-title":"Crit. Care"},{"issue":"1","key":"64223_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/jac\/46.1.150","volume":"46","author":"F de Stoppelaar","year":"2000","unstructured":"de Stoppelaar, F. et al. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J. Antimicrob. Chemother. 46(1), 150\u2013151 (2000).","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"64223_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1128\/AAC.49.4.1337-1339.2005","volume":"49","author":"S Jaruratanasirikul","year":"2005","unstructured":"Jaruratanasirikul, S., Sriwiriyajan, S. & Punyo, J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob. Agents Chemother. 49(4), 1337\u20131339 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64223_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jcrc.2020.08.027","volume":"60","author":"U Liebchen","year":"2020","unstructured":"Liebchen, U. et al. The ONTAI study\u2014A survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units. J. Crit. Care 60, 260\u2013266 (2020).","journal-title":"J. Crit. Care"},{"issue":"6","key":"64223_CR16","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/QCO.0000000000000755","volume":"34","author":"M Gatti","year":"2021","unstructured":"Gatti, M. & Pea, F. Continuous versus intermittent infusion of antibiotics in gram-negative multidrug-resistant infections. Curr. Opin. Infect. Dis. 34(6), 737\u2013747 (2021).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"64223_CR17","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3389\/fmicb.2019.02777","volume":"10","author":"X Song","year":"2019","unstructured":"Song, X. et al. Is Meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? A pharmacokinetic\/pharmacodynamic modeling with monte carlo simulation. Front. Microbiol. 10, 2777 (2019).","journal-title":"Front. Microbiol."},{"key":"64223_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.06389-11","volume":"56","author":"FS Taccone","year":"2012","unstructured":"Taccone, F. S. et al. Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob. Agents Chemother. 56, 2129\u20132131 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64223_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02103-17","author":"CM Rubino","year":"2018","unstructured":"Rubino, C. M. et al. Single-dose pharmacokinetics and safety of meropenem-vaborbactam in subjects with chronic renal impairment. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02103-17 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"64223_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jac\/36.suppl_A.35","volume":"36","author":"HC Kelly","year":"1995","unstructured":"Kelly, H. C., Hutchison, M. & Haworth, S. J. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J. Antimicrob. Chemother. 36, 35\u201341 (1995).","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"64223_CR21","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig, W. A. The pharmacology of meropenem, a new carbapenem antibiotic. Clin. Infect. Dis. 24(2), S266\u2013S275 (1997).","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"64223_CR22","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1128\/AAC.34.8.1515","volume":"34","author":"R Wise","year":"1990","unstructured":"Wise, R. et al. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob. Agents Chemother. 34(8), 1515\u20131517 (1990).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"64223_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF03189806","volume":"22","author":"HK Jones","year":"1997","unstructured":"Jones, H. K. et al. A comparison of the pharmacokinetics of meropenem after intravenous administration by injection over 2, 3 and 5 minutes. Eur. J. Drug Metab. Pharmacokinet. 22(3), 193\u2013199 (1997).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"3","key":"64223_CR24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/jac\/dkg378","volume":"52","author":"S Jaruratanasirikul","year":"2003","unstructured":"Jaruratanasirikul, S. & Sriwiriyajan, S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J. Antimicrob. Chemother. 52(3), 518\u2013521 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"64223_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jac\/24.suppl_A.311","volume":"24","author":"RP Bax","year":"1989","unstructured":"Bax, R. P. et al. The pharmacokinetics of meropenem in volunteers. J. Antimicrob. Chemother. 24, 311\u2013320 (1989).","journal-title":"J. Antimicrob. Chemother."},{"key":"64223_CR26","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/jac\/24.suppl_A.265","volume":"24","author":"MP Harrison","year":"1989","unstructured":"Harrison, M. P. et al. The disposition and metabolism of meropenem in laboratory animals and man. J. Antimicrob. Chemother. 24, 265\u2013277 (1989).","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"64223_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jac\/27.2.219","volume":"27","author":"LA Burman","year":"1991","unstructured":"Burman, L. A. et al. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother. 27(2), 219\u2013224 (1991).","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"64223_CR28","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1128\/AAC.36.7.1437","volume":"36","author":"B Ljungberg","year":"1992","unstructured":"Ljungberg, B. & Nilsson-Ehle, I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob. Agents Chemother. 36(7), 1437\u20131440 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"64223_CR29","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1128\/AAC.36.12.2794","volume":"36","author":"A Leroy","year":"1992","unstructured":"Leroy, A. et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob. Agents Chemother. 36(12), 2794\u20132798 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"64223_CR30","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","volume":"49","author":"WA Krueger","year":"2005","unstructured":"Krueger, W. A. et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49(5), 1881\u20131889 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"64223_CR31","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1592\/phco.23.8.988.32878","volume":"23","author":"PK Dandekar","year":"2003","unstructured":"Dandekar, P. K. et al. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 23(8), 988\u2013991 (2003).","journal-title":"Pharmacotherapy"},{"issue":"2","key":"64223_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01964413","volume":"10","author":"I Nilsson-Ehle","year":"1991","unstructured":"Nilsson-Ehle, I. et al. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10(2), 85\u201388 (1991).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"4","key":"64223_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","volume":"9","author":"E Wenzler","year":"2020","unstructured":"Wenzler, E. & Scoble, P. J. An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam. Infect. Dis. Ther. 9(4), 769\u2013784 (2020).","journal-title":"Infect. Dis. Ther."},{"key":"64223_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02229-19","author":"NL Mallalieu","year":"2020","unstructured":"Mallalieu, N. L. et al. Safety and pharmacokinetic characterization of nacubactam, a novel beta-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02229-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"64223_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","volume":"64","author":"JA Roberts","year":"2009","unstructured":"Roberts, J. A. et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 64(1), 142\u2013150 (2009).","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"64223_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0924-8579(01)00474-5","volume":"19","author":"R Kitzes-Cohen","year":"2002","unstructured":"Kitzes-Cohen, R. et al. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int. J. Antimicrob. Agents 19(2), 105\u2013110 (2002).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"10","key":"64223_CR37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/0091270006291035","volume":"46","author":"C Li","year":"2006","unstructured":"Li, C. et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46(10), 1171\u20131178 (2006).","journal-title":"J. Clin. Pharmacol."},{"issue":"1","key":"64223_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/dku354","volume":"70","author":"F Frippiat","year":"2015","unstructured":"Frippiat, F. et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: The PROMESSE study. J. Antimicrob. Chemother. 70(1), 207\u2013216 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"64223_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13111861","author":"DH Lee","year":"2021","unstructured":"Lee, D. H. et al. Population pharmacokinetics of meropenem in critically ill korean patients and effects of extracorporeal membrane oxygenation. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics13111861 (2021).","journal-title":"Pharmaceutics"},{"issue":"1","key":"64223_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13613-019-0622-8","volume":"10","author":"AT Kothekar","year":"2020","unstructured":"Kothekar, A. T. et al. Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: Implications for empirical therapy against Gram-negative bacteria. Ann. Intensive Care 10(1), 4 (2020).","journal-title":"Ann. Intensive Care"},{"issue":"1","key":"64223_CR41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13054-020-2763-4","volume":"24","author":"A Benitez-Cano","year":"2020","unstructured":"Benitez-Cano, A. et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: A randomized pharmacokinetic trial. Crit. Care 24(1), 55 (2020).","journal-title":"Crit. Care"},{"issue":"4","key":"64223_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jac\/43.4.523","volume":"43","author":"F Thalhammer","year":"1999","unstructured":"Thalhammer, F. et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J. Antimicrob. Chemother. 43(4), 523\u2013527 (1999).","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"64223_CR43","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1128\/AAC.01330-10","volume":"55","author":"TP Lodise","year":"2011","unstructured":"Lodise, T. P. et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob. Agents Chemother. 55(4), 1606\u20131610 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"64223_CR44","doi-asserted-by":"publisher","first-page":"e0260620","DOI":"10.1128\/AAC.02606-20","volume":"65","author":"M Trang","year":"2021","unstructured":"Trang, M. et al. Population pharmacokinetics of meropenem and vaborbactam based on data from noninfected subjects and infected patients. Antimicrob. Agents Chemother. 65(9), e0260620 (2021).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64223-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:07:34Z","timestamp":1724144854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-64223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["64223"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-64223-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3853740\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19269"}}